Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 97

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 97
---
 any time hold a long or short position or otherwise effect transactions in such securities or financial instruments. In addition, Citi and its affiliates (including Citigroup Inc. and its affiliates) may maintain
relationships with STAAR, Alcon Inc., and their respective affiliates. As of August 1, 2025, Citi held, on a proprietary basis, less than 1.0% of the outstanding equity securities of (i) STAAR and (ii) Alcon Inc., respectively.

STAAR selected Citi to act as its financial advisor in connection with the Merger based on Citi’s reputation, experience and
familiarity with STAAR and its business. Citi is an internationally recognized investment banking firm that regularly engages in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings,
competitive bids, secondary distributions of listed and unlisted securities, private placements and valuations for estate, corporate and other purposes.

-58-

Certain Unaudited Prospective Financial Information

STAAR has from time to time provided financial guidance to investors, which has been limited given, among other reasons, the inherent
difficulty of predicting financial performance for future periods and the uncertainty, unpredictability and subjectivity of underlying assumptions and estimates. In connection with the Merger, prior to the execution of the Merger Agreement,
management prepared and provided certain nonpublic financial projections regarding STAAR’s future operations to the Board, Citi and Alcon, in each case as described below.

Upon discussion with and at the direction of the Board, STAAR’s management prepared certain unaudited prospective financial information
for STAAR on a standalone basis for fiscal years 2025 through 2030, as reflected below (the “Projections”), which assumed an annual net sales growth rate of approximately 10% beginning in 2027.

In advance of the Projections being finalized and approved by the Board, STAAR management prepared certain preliminary unaudited prospective
financial information for STAAR on a standalone basis for fiscal years 2025 through 2027, as summarized below (the “July Diligence Projections” and together with the Projections, the “financial projections”). The July
Diligence Projections were provided to Alcon in July 2025 as part of its due diligence process. Following the preparation of the July Diligence Projections, STAAR’s management team continued to refine and assess its estimates and judgments for
STAAR’s future operations, incorporating further risk-adjusted